Spruce

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. The lead focus for the company is the treatment of a rare condition MPS IIIB (Sanfilippo Syndrome Type B), for which current options are limited. It will file for approval for its TA-ERT treatment in Q4’26. Spruce went public in October 2020, listing on Nasdaq with the ticker: SPRB.